Aptorum Group Limited (APM)
NASDAQ: APM · Real-Time Price · USD
1.320
-0.080 (-5.71%)
At close: Dec 5, 2025, 4:00 PM EST
1.290
-0.030 (-2.27%)
After-hours: Dec 5, 2025, 5:57 PM EST
Aptorum Group Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
1
Market Cap
10.75M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
APM News
- 16 days ago - DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference - GlobeNewsWire
- 23 days ago - Andean Precious Metals Corp. (APM:CA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering - GlobeNewsWire
- 2 months ago - As part of the planned merger with DiamiR Biosciences, Aptorum Group will expand its board and management team with seasoned executives - GlobeNewsWire
- 3 months ago - Aptorum Group and DiamiR Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - Why Is Nano-Cap Aptorum Stock Rallying On Thursday? - Benzinga
- 3 months ago - DiamiR Biosciences and Aptorum Group Announce New York State Approval for DiamiR's APOE Genotyping Test - GlobeNewsWire
- 4 months ago - Andean Precious Metals Corp. (ANPMF) Q2 2025 Earnings Call Transcript - Seeking Alpha